This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Aug. 13, 2002 -- A study of vascular endothelial growth factor (VEGF) reported in the Aug. 15 issue of Cancer may help explain the biological basis for the link between social support and cancer ...

AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals ...

Showed high-affinity binding to both human and cynomolgus monkey VEGF-A and PD-1; Effectively blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner; and Demonstrated potent ...

Summit Therapeutics Inc.’s presentation for bispecific antibody ivonescimab in non-small-cell lung cancer could draw some extra attention at next month’s World Conference on Lung Cancer meeting thanks ...

The literature presented in this review does not indicate a clinically relevant relationship between genetic variations in the VEGF system and the risk of CRC. Hence, these markers will probably not ...

A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final ...